** Brokerage Citi Research downgrades drugmaker Merck MRK.N to "neutral" from "buy", trims PT to $84 from $115
** New PT still implies 8.7% upside to the stock's last close
** Brokerage raises concerns about MRK's blockbuster cancer therapy Keytruda losing exclusivity in 2028, which could lead to a 10%-20% decline in sales
** Brokerage sees upside to some of Merck's pipeline products, such as Winrevair, tulisokibart and enlicitide, but notes that the "clock is ticking" for these products to have a significant impact
** Says that the sales recovery of MRK's HPV vaccine Gardasil is progressing at a slower pace than expected
** MRK could benefit from making a large acquisition (over $10 billion) to offset the decline in Keytruda sales, says brokerage
** As of last close, MRK stock down 23% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.